Download the Whitepaper
Non-Invasive Biomarkers of Non-Alcoholic Steatohepatitis and Liver Fibrosis
Non-Invasive Biomarkers of Non-Alcoholic Steatohepatitis and Liver Fibrosis
Learn More About Medpace’s NASH & Liver Disease Capabilities
Our Sponsors gain a competitive edge with our integrated full-service approach in the ever-evolving landscape of NAFLD/NASH drug clinical development. Our experience, coupled with our strong relationships with KOLs and investigative sites as well as our in-house central lab and imaging core lab services, set Sponsors up for long-term success.
You benefit from:
- In-house physicians that are embedded into the study from project initiation to completion, providing hands-on leadership and translating medical knowledge into execution
- Seasoned and highly-trained operational teams with extensive experience in managing GI and hepatology studies, including recent experience in NAFLD/NASH
- Global regulatory experts, including former FDA officials, who can add input, strategy, and efficiencies based on their in-depth understanding of the local and global regulatory landscape